DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1998
INDEX
Anthracyclines, 1713–1715
liposomal, for Kaposi sarcoma, 1823
Anthraquinone laxatives, 1333–1334
effects on bowel function, 1330t
Anthrax, penicillin for, 1487
Antiandrogens, 1668t–1670t
Anti-androgens, 1204–1205,
1765–1766
adverse effects and side effects of,
1763
non-steroidal, 1761f, 1765–1766
mechanism of action of, 1765
steroidal, 1761f, 1765–1766
Antianginal agent(s), 752, 752f,
753–761
amlodipine as, 766–767
antiplatelet drugs as, 752
aspirin as, 767
beta-adrenergic receptor antagonists
as, 752
for unstable angina, 768
calcium-channel blockers as, 752,
766–767
diltiazem as, 766
mechanism of action of, 752
metoprolol as, 767
nitrates as, 756–757, 759–760
buccal administration, 760
cutaneous administration, 760
mechanism of action of, 756–757
oral administration, 759–760
sublingual administration, 759
transmucosal administration, 760
nitroglycerin as, 760
nitrovasodilators as, 752
ranolazine as, 752
statins as, 752
therapeutic uses of, strategies for,
comparison of, 768–771
verapamil as, 766
Antiangiogenesis therapy, 1738–1740
toxicity of, 1739–1740
Antiarrhythmic drugs, 815–848. See
also specific agent
acebutolol, 831–832
action potential-prolonging, 826f
adenosine, 834, 835t
amiodarone, 824t, 827, 834–837,
835t
arrhythmias caused by, 821t, 833
bepridil, 830
beta-adrenergic receptor antagonists,
824t, 828, 831–832 (See also
Beta-adrenergic receptor
antagonists; specific agent)
Antiarrhythmic drugs (Cont.):
bretylium, 837
calcium channel antagonists, 767
calcium-channel blockers, 830–831
(See also Calcium channel
antagonists; specific agent)
classification of, 827–832
contraindications to, 833, 833t
digitalis glycosides, 835t, 837–839
digoxin, 835t, 837–839
diltiazem, 830, 831, 835t
disopyramide, 835t, 839
dofetilide, 835t, 839
dosage and administration of,
835t–836t
dronedarone, 835t, 839–840
electrophysiological actions of, 829t
esmolol, 832, 835t, 840
flecainide, 824t, 828, 835t,
840–841
ibutilide, 835t, 841
isoproterenol, 824t
lidocaine, 824t, 827, 828, 835t,
841–842
magnesium, 824t, 842
mechanism of action of, 823–827
mexiletine, 828, 836t, 842
pharmacokinetics of, 835t–836t
plasma concentration of,
monitoring, 833
principles of use, 832–833
procainamide, 836t, 842–843
propafenone, 836t
properties of, 834–845
propranolol, 828, 831–832, 836t
quinidine, 828, 836t, 843–844
ranolazine, 828
sodium channel blockers, 826f, 827,
827f, 828
toxicity of, 828–829
sotalol, 831–832, 836t, 845
state-dependent ion channel block,
827
therapeutic approaches with,
selection among, 832–833
therapeutic uses of, 834–845
goals, 832
verapamil, 824t, 830, 831, 836t
vernakalant, 845
Antibacterial agents, for neoplastic
disease, 1668t–1670t
Antibiotic(s). See also Antimicrobial
agents
ABC transporters and, 105t, 106t
arrhythmias caused by, 832
Antibiotic(s) (Cont.):
and benzoyl peroxide, combinations,
for acne, 1817
for cancer, 1712–1715
histamine and, 914
for inflammatory bowel disease,
1360
and statins, interactions, 896
systemic
for acne, 1816–1817
for cutaneous infections, 1816
therapeutic uses of, for
inflammatory bowel disease,
1352t
topical, for acne, 1816–1817
Anticancer drugs , polymorphisms and
response to, 159t
Anticholinergic agents, 211–212
anticholinesterase for intoxication
with, 252
for bowel disorders, 1340–1341
for nausea and vomiting, 1344
Anticholinergic toxidrome, 83t
Anticholinergic toxidrome antidote,
86t
Anticholinesterase agents
absorption of, 247
acetylcholinesterase structure and,
240–241
acute intoxication by, 248
“aging” of, 249
for Alzheimer’s disease, 252–253
for anticholinergic intoxication, 252
chemistry of, 242–245
cholinesterase reactivators and, 249
definition of, 239
disposition of, 249
effector organ action, 242
excretion of, 247
eye and, 246, 250–251
gastrointestinal tract and, 246
for glaucoma, 250–251
heart and, 246–247
history of, 239
mechanism of action of, 241–242
for myasthenia gravis, 251–252
neuromuscular junction and, 246
noncovalent, 242
for paralytic ileus, 250
pharmacological properties of,
245–247
as prophylaxis for cholinesterase
poisoning, 252
“reversible” carbamate inhibitors,
242